View Older Stories View More Recent Stories

Jul 20, 2018 04:24PM U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
Jul 18, 2018 06:48AM Pfizer (PFE), Eli Lilly (LLY) Reports Positive Top-Line Results from Phase 3 Trial Of Tanezumab for Treatment of Osteoarthritis Pain
Jul 18, 2018 06:45AM Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Jul 16, 2018 10:31AM Pfizer (PFE), Spark (ONCE) Initiate Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
Jul 16, 2018 10:31AM Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
Jun 28, 2018 01:50PM Pfizer (PFE) Announces XELJANZ Received Marketing Authorisation in EU for Active Psoriatic Arthritis
Jun 28, 2018 01:49PM XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis
Jun 28, 2018 12:20PM Pfizer Declares 34-Cent Third-Quarter 2018 Dividend
Jun 27, 2018 08:04AM Pfizer (PFE) Secures Priority Review Designation and New Drug Application Acceptance for Glasdegib
Jun 27, 2018 08:00AM U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
Jun 25, 2018 08:02AM Pfizer (PFE) Announces OS Results from Phase 3 PALOMA-3 Trial of IBRANCE in HR+, HER2- Metastatic Breast Cancer
Jun 25, 2018 08:00AM Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer
Jun 12, 2018 07:00AM Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness
Jun 7, 2018 08:00AM Pfizer (PFE) Says FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Jun 7, 2018 08:00AM U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Jun 6, 2018 08:01AM Pfizer (PFE) Expands Venture Investing with $600 Million Commitment to Pfizer Ventures
Jun 6, 2018 08:00AM Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures
Jun 5, 2018 05:51AM Pfizer (PFE) Reports Overall Survival Data from ARCHER 1050 Trial Evaluating Dacomitinib as First Line Treatment
Jun 4, 2018 05:37PM Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
Jun 4, 2018 08:06AM Merck Provides Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Showing Continued Durable Responses with BAVENCIO (avelumab)
Jun 4, 2018 08:00AM Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Jun 1, 2018 07:33AM Pfizer (PFE) Reports Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA (trastuzumab)
Jun 1, 2018 07:30AM Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)
May 30, 2018 03:53PM Pfizer (PFE) Announces U.S. FDA Approves XELJANZ for Treatment of Moderately to Severely Active Ulcerative Colitis
May 30, 2018 03:52PM Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
May 29, 2018 08:01AM Pfizer (PFE) Says XALKORI Received FDA Breakthrough Therapy Designation in Two New Indications
May 29, 2018 08:00AM Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
May 23, 2018 08:05AM Pfizer (PFE) Says FDA Granted Breakthrough Therapy Designation for Tafamidis for Treatment of Patients with Transthyretin Cardiomyopathy
May 23, 2018 08:00AM FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
May 22, 2018 01:30PM A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+
May 22, 2018 08:01AM Pfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV Vaccine
May 22, 2018 08:00AM Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
May 22, 2018 05:51AM Spark Therapeutics (ONCE) and Pfizer (PFE) Highlight Data from Ongoing Phase 1/2 Clinical Trial of Investigational SPK-9001 for 15 Patients with Severe/Moderately-Severe Hemophilia B
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 17, 2018 08:04AM Pfizer (PFE) Says LYRICA Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Met Primary Endpoint
May 17, 2018 08:00AM LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
May 16, 2018 05:00PM Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO
May 15, 2018 02:42PM Pfizer (PFE) Announces FDA Approval for Biosimilar RETACRIT
May 15, 2018 02:38PM Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
Apr 26, 2018 01:13PM Pfizer Hosts Annual Meeting of Shareholders
Apr 23, 2018 08:03AM Pfizer (PFE) Announces FDA Breakthrough Therapy Designation for TRUMENBA for Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Apr 23, 2018 08:00AM Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Apr 23, 2018 07:46AM Pfizer (PFE) Receives CRL on Proposed Trastuzumab Biosimilar
Apr 23, 2018 07:45AM Pfizer Provides Update on Proposed Trastuzumab Biosimilar
Apr 23, 2018 07:33AM Pfizer (PFE) Announces MYLOTARG Was Approved in EU For Treatment Of Previously Untreated, De Novo, CD33-positive AML in Combination With Chemotherapy
Apr 23, 2018 07:30AM MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy
Apr 19, 2018 12:38PM Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders
Apr 12, 2018 08:02AM Pfizer (PFE) Commences Phase 1b Clinical Trial for Investigational Mini-Dystrophin Gene Therapy, PF-06939926
View More Recent Stories View Older Stories